¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"perichondral cutaneous graft"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cutaneous neoplasm
    ÇǺÎÁ¾¾ç
  • cutaneous nerve
    ÇǺνŰæ
  • cutaneous nerve ending
    ÇǺνŰæÁ¾¸»
  • cutaneous nerve somatosensory evoked potential
    ÇǺνŰæ¸ö°¨°¢À¯¹ßÀüÀ§
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous ridge
    ÇǺδɼ±
  • cutaneous sarcoidosis
    ÇǺλ縣ÄÚÀ̵åÁõ
  • cutaneous schistosomiasis
    ÇǺÎÁÖÇ÷ÈíÃæÁõ
  • cutaneous sensation
    ÇǺΰ¨°¢
  • cutaneous tag
    ÁãÁ¥
  • cutaneous ureteroileostomy
    ÇǺοä°üµ¹Ã¢ÀÚ¿¬°á(¼ú), ÇǺοä°üȸÀ忬°á(¼ú)
  • cutaneous ureterostomy
    ÇǺοä°ü⳿(¼ú), ÇǺοä°üÁ¶·ç(¼ú)
  • diffuse cutaneous mastocytosis
    ±¤¹üÀ§ÇǺκñ¸¸¼¼Æ÷Áõ
  • deep cutaneous lymphatic capillary network
    ±íÀºÇǺθ²ÇÁ¸ð¼¼°ü±×¹°, ½ÉºÎÇǺθ²ÇÁ¸ð¼¼°ü¸Á
  • femoral cutaneous nerve
    ³Ò´Ù¸®ÇǺνŰæ, ´ëÅðÇǺνŰæ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cutaneous ridge
    ÇǺδɼ±
  • cutaneous sarcoidosis
    ÇǺλ縣ÄÚÀ̵åÁõ
  • cutaneous schistosomiasis
    ÇǺÎÁÖÇ÷ÈíÃæÁõ
  • cutaneous sensation
    ÇǺΰ¨°¢
  • cutaneous sulcus
    ÇǺΰí¶û
  • cutaneous symptom
    ÇǺÎÁõ»ó
  • cutaneous tag
    ÇǺο¬¼º¼¶À¯Á¾
  • cutaneous ureteroileostomy
    ÇǺοä°üµ¹Ã¢ÀÚ¿¬°á¼ú, ÇǺοä°üȸÀ忬°á¼ú
  • cutaneous ureterostomy
    ÇǺοä°ü⳿¼ú
  • cutaneous basophil hypersensitivity
    ÇǺÎÈ£¿°±¸°ú¹Î
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cutaneous lymphoid hyperplasia
    ÇǺθ²ÇÁ°ú´ÙÇü¼º
  • cutaneous mucosal hyalinosis
    ÇǺÎÁ¡¸·À¯¸®ÁúÁõ
  • cutaneous necrotizing venulitis
    ÇǺα«»ç¼¼Á¤¸Æ¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary localized cutaneous amyloidosis
    ¿ø¹ß¼º ±¹¼Ò ÇǺΠÀ¯ÀüºÐÁõ
  • random cutaneous flap
    ÀÓÀÇÇÇÆÇ
  • Graft
    Á¶Á÷À̽Ä(ðÚòÄì¹ãÕ), ÀÌ½ÄÆí(ì¹ãÕø¸)
  • alloplastic graft
    ¹«»ý¹°Àç·áÀÌ½ÄÆí(ÙíßæÚªî§è÷ì¹ãÕø¸).
  • animal graft
    µ¿¹°½ÄÇÇ(¡­½ÄÇÇ).
  • artificial skin graft
    Àΰø ÇǺÎÀ̽Ä
  • free graft
    À¯¸®À̽Ä(À¯ÀÌÀ̽Ä).
  • free graft
    À¯¸®À̽Ä(ë´ìÆì¹ãÕ).
  • free jejunal graft
    À¯¸®°øÀå À̽ļú
  • full thickness graft
    ÀüÃþÇǺÎÀÌ½ÄÆí(¡­ÇǺÎÀÌ½ÄÆí), ÀüÃþ½ÄÇÇ(¡­½ÄÇÇ).
  • full thickness graft
    ÀüÃþÇǺÎÀÌ½ÄÆí(¡­ù«Ý±ì¹ãÕø¸), ÀüÃþ½ÄÇÇ(¡­ãÕù«).
  • gauntlet graft
    Àå°©»ó À̽İñ Æí(íæË¡ßÒì¹ãÖÍéø¸), ±äÀå°©Çü À̽Ä.
  • graft
    ÀÌ½ÄÆí
  • graft
    À̽Ä(Æí)
  • graft
    Á¶Á÷À̽Ä(ðÚòÄì¹ãÕ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cartilage graft
    ¿¬°ñÀ̽Ä
  • chorioallantoic graft
    À¶¸ð¿ä¸·À̽Ä(ëÖÙ¾èñدì¹ãÕ).
  • collagen graft
    ±³¿øÁúÀ̽Ä
  • composite graft
    º¹ÇÕÁ¶Á÷À̽Ä.
  • corneal graft
    °¢¸·ÀÌ½ÄÆí(¡­ì¹ãÖ).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • coronary artery bypass graft
    °ü»óµ¿¸Æ¿ìȸ·Î¼úÀ̽Ä(¼ú).
  • cultured keratinocyte graft
    ¹è¾ç°¢Áú¼¼Æ÷ À̽Ä
  • dermic graft
    ½ÄÇÇ(½ÄÇÇ).
  • dermis graft
    ÁøÇÇÀ̽Ä
  • double-end graft
    ½Ö´ÜÀ̽Ä.
  • dural graft
    °æ¸·À̽Ä(°æ¸·À̽Ä).
  • epidermic graft
    Ç¥ÇÇÀ̽Ä(¡­ì¹ãÕ).
  • fascia graft
    ±Ù¸· À̽Ä(ÐÉØ¯ì¹ãÕ).
  • fat graft
    Áö¹æÀÌ½ÄÆí(¡­ÀÌ½ÄÆí).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Medial dorsal cutaneous nerve
    ¾ÈÂʹߵîÇǺνŰæ
    [¿¾ ¿ë¾î] ³»ÃøÁ·¹èÇǽŰæ
  • Medial cutaneous nerve of forearm
    ¾ÈÂʾƷ¡ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ³»ÃøÀü¿ÏÇǽŰæ
  • Medial cutaneous nerve of arm
    ¾ÈÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãø»ó¿ÏÇǽŰæ
  • Medial sural cutaneous nerve
    ¾ÈÂÊÀåµýÁöÇǺνŰæ
    [¿¾ ¿ë¾î] ³»Ãøºñº¹ÇǽŰæ
  • Medial cutaneous branches of leg
    ¾ÈÂÊÁ¾¾Æ¸®ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÏÅðÇÇÁö
  • Medial cutaneous branch
    ¾ÈÂÊÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ³»ÃøÇÇÁö
  • Anterior cutaneous branch (of thorax)
    ¾Õ(°¡½¿)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(Èä)ÇÇÁö
  • Anterior cutaneous branch (of abdomen)
    ¾Õ(¹è)ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] Àü(º¹)ÇÇÁö
  • Anterior cutaneous branch
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Anterior cutaneous branches
    ¾ÕÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÀüÇÇÁö
  • Superior lateral cutaneous nerve of arm
    À§°¡ÂÊÀ§ÆÈÇǺνŰæ
    [¿¾ ¿ë¾î] »ó¿ÜÃø»ó¿ÏÇǽŰæ
  • Intermediate dorsal cutaneous nerve
    Áß°£¹ßµîÇǺνŰæ
    [¿¾ ¿ë¾î] ÁßÁ·¹èÇǽŰæ
  • Cutaneous branch
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
  • Cutaneous branches
    ÇǺΰ¡Áö
    [¿¾ ¿ë¾î] ÇÇÁö
  • Cutaneous sulci
    ÇǺΰí¶û
    [¿¾ ¿ë¾î] ÇǺμұ¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PCNA Per-Cutaneous Needle Aspiration of lung
S.C. Sub Cutis; Sub-Cutaneous(ly) injection; ÇÇÇÏ·Î, ÇÇÇÏÁÖ»ç
SCLE Subacute Cutaneous Lupus Erythematosus
BCPV bovine cutaneous papilloma virus
B-K initials of two patients after whom a multiple cutaneous nevus [mole] was named
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CLA Cutaneous Lymphocyte-associated Antigen
CTCL Cutaneous T cell lymphoma
CBH Cutaneous basophil hypersensitivity
CBF Cutaneous blood flow
CLA Cutaneous lymphocyte antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cutaneous metastatic carcinoma
    ÇǺΠÀüÀÌ ¾Ï, ÇǺΠÀüÀÌ ¾ÏÁ¾
  • cutaneous myxoid cyst
    ÇǺΠÁ¡¾×¾ç ³¶Á¾
  • cutaneous nerve
    ÇǺΠ½Å°æ, ÇÇ ½Å°æ
  • cutaneous nociceptor
    ÇÇºÎ Ä§ÇØ ¼ö¿ëü, ÇǺΠÀ¯ÇØ ¼ö¿ë±â
  • cutaneous part
    ÇǺΠÆí
  • cutaneous polymodal nociceptor
    ÇǺΠ´ÙÇü Ä§ÇØ ¼ö¿ëü, ÇǺΠ´ÙÇü À¯ÇØ ¼ö¿ë±â
  • cutaneous pseudolymphoma
    ÇǺΠ°¡¼º ¸²ÇÁÁ¾
  • cutaneous reaction
    ÇǺΠ¹ÝÀÀ
  • cutaneous region
    ÇǺΠºÎÀ§
  • cutaneous spot
    ÇǺΠ¹Ý, ÇǺΠ¹ÝÁ¡
  • cutaneous symptom
    ÇǺΠÁõ»ó
  • cutaneous trigger point
    ÇǺΠ¹ßÅëÁ¡
  • cutaneous vein
    ÇǺΠÁ¤¸Æ, ÇÇÁ¤¸Æ
  • familial cutaneous collagenosis
    °¡Á·¼º ÇǺΠ±³¿øÁõ
  • laryngo-onycho-cutaneous syndrome
    ÈĵÎ-¼Õ ¹ßÅé-ÇǺΠÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
brephoplastic graft A graft from an embryo or newborn to an adult.
(05 Mar 2000)
bypass graft <surgery> An alternative blood vessel that is created by a surgeon to reroute blood flow. Grafts may be synthetic (dacryon) or autologous (a vein from the patients own leg used as a substitute for the diseased vessel).
(20 Mar 1998)
cable graft A multiple strand nerve graft arranged as a pathway for regeneration of axons.
(05 Mar 2000)
vascularised graft The state of a graft after the recipient vasculature has been connected with the vessels in the graft.
(05 Mar 2000)
partial-thickness graft A graft of portions of the skin, i.e., the epidermis and part of the dermis, or of part of the mucosa and submucosa, but not including the periosteum.
Synonym: partial-thickness graft, split-skin graft.
(05 Mar 2000)
pedicle graft A skin flap sustained by a blood-carrying stem from the donor site during transfer, in periodontal surgery, a flap used to increase the width of attached gingiva, or to cover a root surface, by moving the attached gingiva, which remains joined at one side, to an adjacent position and suturing the free end.
(05 Mar 2000)
Reverdin graft Small bits of skin, of partial or full thickness, removed from a healthy area and seeded in a site to be covered.
Synonym: Reverdin graft.
(05 Mar 2000)
graft To insert scions from one tree, or kind of tree, etc, into another; to practice grafting.
A small shoot or scion of a tree inserted in another tree, the stock of which is to support and nourish it. The two unite and become one tree, but the graft determines the kind of fruit.
A branch or portion of a tree growing from such a shoot.
<surgery> A portion of living tissue used in the operation of autoplasty.
Origin: OE. Graff, F. Greffe, originally the same word as OF. Grafe pencil, L. Graphium, Gr, fr. To write; prob. Akin to E. Carve. So named from the resemblance of a scion or shoot to a pointed pencil. Cf. Graphic, Grammar.
1. To insert (a graft) in a branch or stem of another tree; to propagate by insertion in another stock; also, to insert a graft upon. [Formerly written graff.
2.
<surgery> To implant a portion of (living flesh or akin) in a lesion so as to form an organic union.
3.
To join (one thing) to another as if by grafting, so as to bring about a close union. "And graft my love immortal on thy fame !" (Pope)
4.
To cover, as a ring bolt, block strap, splicing, etc, with a weaving of small cord or rope-yarns.
Origin: F. Greffer. See Graft.
Source: Websters Dictionary
(01 Mar 1998)
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
graft occlusion <physiology> Obstruction of flow in biological or prosthetic vascular grafts.
(12 Dec 1998)
graft rejection <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take.
(16 Dec 1997)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á